2nd Annual Pharma Market Access and Pricing Summit Asia

2018年9月19-20日 • 新加坡, One Farrer Hotel & Spa

概要

亞洲醫藥市場極其複雜。各國市場皆基於醫療政策、償還制度、價格決定方法進行管理,但是每個國家之間有著巨大差異,進入市場時必須對於風險之大有所準備,因此需要關注對應個別診療科的高價醫藥品與治療方法。販售、轉讓專利是處理此問題的方法之一,雖可減低風險,但必須做好利益下降的準備,也無法保證成功。

第2屆Pharma Market Access Asia 2018將聚集製藥業界中各組織的代表,討論在艱困環境中找出方向的策略,並發表在稀有藥或高價治療法、學名藥、生物仿製等領域成功進入市場、確保利益的做法與教訓等。

"Excellent event! Looking at multiple perspective from patients, policy maker, prescriber, provider, and payers. Well done to the producer and organizing team!"
Sebastien Boisseau, Market Access Director, Mundipharma

本次峰會值得注目之處

  • 各國製藥公司市場進入案例研究
  • 生物仿製、學名藥、稀有藥等應注目的成長市場與戰略
  • 定價和償還─改善市場進入做法的策略
  • 活用HEOR與RWE─支持市場進入的資訊
  • 轉讓專利與合作─可期待成功的合作模式

同時舉行的活動

2nd Annual Accelerating Clinical Trials in Asia 2018 >>
11th Annual Pharma Regulatory Affairs Summit 2018 >>
Digital Pharma >>

議程

8:00 am

Main Conference Registration and Morning Coffee

PHARMACON ASIA OPENING PLENARY SESSION

9:00 am

Addressing on skilled talent, strong manufacturing capabilities and thriving research ecosystem in pharmaceutical firms to set up to serve patients and connect with the growing Asian market

9:30 am

[Industry Address] Integrating Silicon with Drugs: Pushing the Boundaries of Pharma Manufacturing with Digital Medicines

Nik Leist, Senior Director, Ingestible Sensor Manufacturing/Site Leader, Proteus Digital Health, USA

10:40 am

Morning Networking and Refreshment Break. End of Plenary Session

PHARMA MARKET ACCESS & PRICING SUMMIT CONTINUES

11:10 am

Chairperson's Opening Remarks

EMERGING MARKETS AND GROWTH SEGMENTS

11:20 am

  • Pricing and reimbursement governance
  • Implementing best practices, policies and tools for enhanced pricing decisions in private and reimbursed markets
  • Adapting market access strategies for growth regions (Japan, Korea & China markets) in Asia

11:50 am

  • Understanding the current landscape in ANZ in light of reimbursement models and payer needs
  • Effectively managing stakeholder expectations and aligning market strategies
  • Utilizing HEOR to formulate effective pricing strategies

1:00 pm

Networking Lunch

HEOR AND RWE FOR MARKET ENTRY AND EXPANSION

2:00 pm

  • Overview of evidence-driven approach for strategic planning in Asia Pacific
  • How HEOR/RWE can support pricing and market access in different product lifecycle?
  • Leveraging retrospective and prospective real world data to strengthen product value communication with relevant stakeholders

2:30 pm

  • Design and implement cost-minimization and cost-effectiveness models to support local product adoption
  • Implement clinical and economic studies to generate outcome data and support local reimbursement submissions
  • Ensuring successful health economics, pricing and tender outcomes through strategic internal and external collaborations

3:00 pm

  • Due to the scarcity of patients and knowledge on rare diseases, orphan drugs often pose challenges to patients, payers, regulatory authorities and legislators.
  • Also, when introducing a new drug, it is always important that the pharmaceutical company recognizes differences in access procedures by country, which are more complicated in orphan drugs.
  • All the pharmaceutical companies who aim to benefit rare disease patients in the region need to understand the current state of the art surrounding the access procedures, which are progressing daily but still have many complications country by country.

3:30 pm

Afternoon Networking & Refreshment Break

INNOVATIVE PHARMA-STAKEHOLDER COLLABORATION MODELS

4:00 pm

Addressing Payer Needs: Payer Insights from An Insurer's Perspective

  • Fueling data-driven healthcare through big data & healthcare analytics
  • Improving collaborations between pharma & insurers, in terms of data sharing to derive costs
  • Consolidating real-world patient data for coverage decisions and value-based payments
  • Current medical insurance and claims regulation landscape for patients in HK
  • Factors affecting medical coverage of patients and costs involved
  • Enabling affordability for patients and better long-term treatment options
  • Better drugs for lesser side effects and the importance of preventive medicine

5:30 pm

Networking Cocktail

8:50 am

Chairperson's Opening Remarks

VALUE-BASED PRICE MODELLING AND REIMBURSEMENT STRATEGIES

9:00 am

  • Moving away from traditional fee-for-service reimbursement models to value-based pricing models
  • Adapting pricing and rebate strategies for multiple entities in a multi-payer system
  • Driving efforts to shape external healthcare policy to mitigate short-term business risk and maximize long-term value

9:30 am

  • Overview of reimbursement and pricing approval process in Taiwan
  • Critical criteria for pricing and reimbursement of drugs
  • Accelerating patient access to new drugs, improving affordability and mitigating reimbursement costs

10:00 am

  • Rising drug prices have made payers ever more aware of the risks and impacts of cost blowouts
  • Reviewing Australia's PBS system and how its several mechanisms (HTA, MES, PfP & RSAa) are being used to manage costs and maximize program value
  • Maximizing access to innovative drugs whilst limiting expenditure on cost ineffective interventions

10:30 am

Morning Networking & Refreshment Break

COST, ASSESSMENT AND PRICING

11:00 am

  • Reviewing current landscape in Thailand (UHC scheme, reimbursement model, govt policy)
  • Performing comparative clinical effectiveness, cost-effectiveness and budget impact assessment of new drugs
  • Working with stakeholders to build capacity for HTA in Thailand and at the global level

11:30 am

  • Brief overview of pricing in key mature markets for high-priced drugs (including Japan)
  • Presentation of pricing analysis of a number of analogues looking at yearly vs. lifetime costs per patient
  • Discussion on potential alternative ways to think about pricing innovative drugs

12:00 pm

  • Closing gaps in molecular medicine today, to open up more novel treatment options for patients
  • Expanding patient-access within Asia-Pacific
  • Taking personalised healthcare in oncology to the next level

12:30 pm

Networking Lunch

ORPHAN DRUGS AND INNOVATIVE MEDICINE

1:30 pm

  • With increasing patient lifespan, demand for innovative medicine will continue to grow
  • Adapting market access strategies for new product launches and originator molecules
  • Accelerating the flow of potential new medicines from pipeline to the market

2:00 pm

  • Country specific measures taken to promote the development and commercialization of orphan drugs
  • Pricing and reimbursement strategies for developed markets
  • Delivering breakthrough therapies for rare disease patients

STRATEGY FOR NEW PRODUCT LAUNCHES

2:30 pm

  • Identifying pre-commercialisation molecules for new product planning
  • Defining launch excellence frameworks for new product launches in specialty care portfolio
  • Meeting launch deliverables, optimizing launch outcomes and mitigating risks
  • For speaking opportunities, please contact:
    Siang-Yee Tel: +65 65082446 | Email: siangyee.yeo@ibcasia.com.sg

3:30 pm

Afternoon Networking & Refreshment Break

PHARMACON ASIA 2018 CLOSING PLENARY SESSIONS

5:00 pm

Chairperson's Summary and End of Main Conference Day Two

* 活動內容有可能不事先告知作更動及調整。

贊助商募集

參加成為Pharma Market Access and Pricing Summit Asia的夥伴,可提高知名度。
利用本活動成為引領市場的企業、確保地位,可發揮各種機會進行品牌行銷與市場行銷。請聯繫我們以瞭解更多資訊。

演講者

Ho Weng Si

Director, Biomedical Sciences Group, Economic Development Board, Singapore

Nik Leist

Senior Director, Ingestible Sensor Manufacturing/Site Leader, Proteus Digital Health, USA

Enver Erkan

Country Manager, Pfizer Singapore

Alexis Serlin

Asia Cluster Head, Novartis

Miguel Angel Rivera Tapia

Global Digital Innovation Lead, Ferring Pharmaceuticals, Switzerland

How Ti-Hwei

Country President, AstraZeneca, Singapore

Robert Tan

Head of Market Access, Asia, Vifor Pharma, Singapore

Matt Slabbert

Head of Market Access, ANZ, Bayer, Australia

Kathleen Yeoh

Director, Corporate Affairs and Market Access, ASEAN, Eli Lilly & Company, Malaysia

Jie Shen

Corporate Global Head of Pricing and Value Policy, Novartis, Switzerland

Jamie (Min) Zhang

Head of Value Demonstration & Access APAC, Shire, China

Sirinthip Petcharapiruch

Head of HEOR, Real-World Insights, IQVIA Asia Pacific

Laurent Metz

HEMA Lead Asia Pacific - Medical Devices Sector, Johnson & Johnson, Singapore

Yuki Sato

Representative Director, Deallus Consulting, Japan

Min Su

Director, Healthcare Analytics - Group Healthcare, AIA, Hong Kong

Chan Wing Sze Cherry

Group Medical Advisor, AIA, Hong Kong

Yoshihiro Suwa

Partner, Head of Healthcare Southeast Asia, PT Roland Berger, Indonesia

Nathan Kothandaraman

Market Access & Government Affairs, Johnson & Johnson, Malaysia

Teck Jack Tan

Medical Director, Northeast Medical Group, Singapore

Timothy Low

Board of Director, Farrer Park Hospital l APAC Medical Head, Shire l Board of Director, PACRA, Singapore

Evelyn Pang

Head of Operations, Sanofi, Singapore

Yu-Wen Huang

Senior Executive Officer, Medical Review and Pharmaceutical Benefits Division, National Health Insurance Administration, Ministry of Health and Welfare, Taiwan

Gregory O'Toole

Reimbursement Strategy Specialist, AstraZeneca, Australia

Waranya Rattanavipapong

Head of International Unit, Health Intervention and Technology Assessment Program (HITAP), Ministry of Public Health, Thailand

Neal Somchand

Principal, Deallus Consulting, Japan

Devmanyu Singh

Regional Business Development (APAC), Roche, Singapore

Hazel Dy Tioco

Asia Pacific Regional Director, Study Management and Logistics, Sanofi, Philippines

Yaron Turpaz

Chief Data & Technology Officer, Managing Director, Global Gene Corp, Singapore

Harish Dave

Co-Founder and Chief Medical Officer, Aum Biosciences, Singapore

活動日期與地點

2018年9月19-20日

新加坡, One Farrer Hotel & Spa
1 Farrer Park Station Road
Singapore 217562

Contact Person: Daniel Koh
DDI: (+65) 6705 7884
Fax: (+65) 6834 7892
Cell: (+65) 86870123
Email: danielkoh@onefarrer.com

合作夥伴

Media Partners

APBN serves as a knowledge exchange platform (print and online) to provide latest news and noteworthy information in biotechnology, healthcare, biomedical and pharmaceutical industry in Asia Pacific. Established in 1997, APBN is the first and only monthly magazine focused on biotechnology, healthcare, pharmaceutical and life science developments in China and other Asia Pacific countries. The main motivation of APBN is to bring biotechnology news in a comprehensive and concise manner to, but not limited to, clinicians, research scientists, students, and other industry professionals and experts.

Bentham Science Publishers is rendering a vital service in the quality publication that publishes over 100 peer-reviewed print and online scientific, technical and medical journals. These titles are indexed in recognized indexing agencies, such as Science Citation Index®, Journal Citation Reports/Science Edition, MEDLINE/Index Medicus, PubMed, Scopus, Chemical Abstracts, EMBASE etc. Some of the high impact titles which enjoy a wide reach and distribution are Gene Therapy (Impact Factor 4.906), Alzheimer Research (Impact Factor 3.796), Medicinal Chemistry (Impact Factor 3.715), and other popular titles.

Bentham has an extensive library of eBooks in the areas of science, technology, medicine, social sciences and humanities. Bentham eBooks publishes monographs, handbooks, conference proceedings, textbooks, review volumes, biographies and autobiographies.

Established since 1998, Bio-Equip is a leading website for lab equipments, reagents, consumables and bio services. Our users come from different fields like life science, medical research, pharmaceutical, biotechnology, modern agriculture, food safety and environment monitoring. Bio-Equip offer users a complete product directory which involves 158 product ranges among lab equipments, reagents, consumables, lab animals, bio services, cell lines, bio software and books.Serving users through two websites, www.bio-equip.com (Chinese) and www.bio-equip.cn (English), we own over 20,000 registered suppliers and more than 500,000 pieces of product and technical service information with details of product description, price, sample downloading, technical articles and videos.

KONGPOSH Publications is one of the leading Pharma publishers of India. Our publications are - The Pharma Review® is a bi-monthly article based journal. Covering news, views and articles on various fields of pharmacy including Clinical Trials, Biotechnology, Review/Research papers, Herbal Medicine and much more. Contributions received from Eminent pharma personalities from India as well as other countries which helps us to have a varied and rich content matter. Participation and distribution in over 20 Expos & Conferences worldwide each year. It is widely read by decision makers, middle management and the academia. The journal is Abstracted & Indexed in International Pharmaceutical Abstract & Chemical Abstract - USA, Index Copernicus - Poland & Ulrich's Journal Database- USA for the quality of its content. Also available on our website and E-book format.

For regular complimentary link of the journal write to us on kongposhpub@gmail.com.

SOURCE newswire provides comprehensive coverage of breaking news for the life sciences industry in China. Daily updates allow timely tracking of key company developments, deal-making, and regulatory trends, with the primary focus on the pharmaceutical industry.

  • Daily News Briefs: receive 3-4 original articles each day
  • Email alerts on topics of interest by keyword.
  • Access a fully searchable archive of 20,940 original articles
  • Filter news by story type: company news; product/R&D trends; pricing and reimbursement decisions; and general policy developments
  • Ability to save and share favorite news items.

Lingmed Ltd was founded in 2013 in Hong Kong, ly we have offices in Shanghai and Beijing. Lingmed promotes three leading intelligence databases for healthcare professionals in China to make better decisions. Lingmed’s core products are healthcare intelligence databases; it covers global innovative assets & China market intelligence. Lingmed’s Products and Services have been recognized by Fortune 500 multinational pharma and device companies as well as Chinese local big pharmacos. In addition, we together with our partners in Europe provide partnering services to bridge European and Chinese pharmaceuticals with biotech companies, including valuation and market monitoring reports.

In the realm of Pharmacy, where innovation is rapid, Pharmaceutical-Tech stands adept at conceptualizing unique ideas relevant to the B2B space. Pharmaceutical-Tech is essentially a B2B online business, technology media platform and global magazine that have under its wraps the largest global database of Pharmacy buyers and suppliers. Pharmaceutical-Tech.com covers in-depth trends that shape industry dynamics and metamorphose global economics. With services like search engine optimization, global magazine, social media marketing, product video showcase, e-mail marketing, e-newsletter sponsorship, banner advertising, event marketing and micro-website within our platform, www.pharmaceutical-tech.com has created a recognition that spans over a global audience, thereby revolutionizing how businesses transact.

Pharma China (www.pharmachinaonline.com) is the most trusted English media and business intelligence service covering the Chinese pharmaceutical / biopharmaceutical industry and market.

Pharma China caters for the growing needs of the international pharmaceutical industry for up-to-date and insightful information and intelligence on China's burgeoning but increasingly complex healthcare marketplace, and is subscribed by most multinational pharmaceutical companies, leading CROs, investment banks and consulting firms active in China as well as relevant industry associations and government agencies.

  • Pharma China Journal Edition (monthly in PDF and Print)
  • Pharma China Web Edition (continuously-updated news, in-depth commentaries and online databases)
  • China Pharmaceutical Guide (the most comprehensive and authoritative reference for China's healthcare sector)

Pharma Focus Asia is a quarterly magazine from Ochre Media Pvt. Ltd. Pharma Focus Asia covers important issues and trends shaping the future of the Pharma industry across Asia and rest of the world. It is the leading Pharma title in print as well as digital versions serving the information needs of key executives from the world's leading pharmaceutical companies.

Informa's Pharma Intelligence is the trusted partner of the top 50 global pharmaceutical companies and the top 10 contract research organisations (CRO's) – providing timely intelligence and insight to help them make authoritative decisions.

From drug and device discovery and development to regulatory approval, drug reimbursement to lifecycle management – we provide the global intelligence and insight to help advance our partners' initiatives in a fast changing market.

Pharmalicensing (www.pharmalicensing.com) is the premier biopharmaceutical Open Innovation resource designed for professionals involved with partnering, licensing and business development worldwide.

Actively supporting all forms of partnering and in- and out-licensing activities, Pharmalicensing utilizes the unique online Showcase Profiling & Discover services, as well as its renowned Partnering Search service leveraging its global network of industry experts, to enable companies to identify and engage with appropriate partners around the world. Pharmalicensing is actively utilized by many tens of thousands of industry professionals each month. Pharmalicensing is a division of IP Technology Exchange, Inc.

Technology Networks scientific communities offer today's scientists a single resource that contains unique, engaging, and entertaining content from their field of research.

 

免費電子郵件通知服務